Circulating tumor cells in gastric cancer: developments and clinical applications

Clin Exp Med. 2023 Dec;23(8):4385-4399. doi: 10.1007/s10238-023-01158-2. Epub 2023 Aug 7.

Abstract

Circulating tumor cells (CTCs), which are shed from primary tumor or metastatic sites into the bloodstream and subsequently seed into distant tissues, are considered as the precursors of metastases. Gastric cancer (GC) is a highly heterogeneous malignant tumor. With regard to the diagnosis of GC, secondary pathological biopsy is difficult, while invasive examination is harmful to patients. In recent years, CTCs have made great progress in tumor diagnosis, prognosis prediction, efficacy detection and treatment guidance, but the research on the role of CTCs in GC remains limited. The following sections review the landmark studies demonstrating the technical approaches of CTCs monitoring in the field of GC. Moreover, we highlight the clinical application of CTCs numbers and phenotypes in monitoring the therapeutic efficacy and judging patient prognosis by sequential blood analyses.

Keywords: Blood analyses; Circulating tumor cells (CTCs); Clinical application; Gastric cancer (GC); Technical approach.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor
  • Biopsy
  • Humans
  • Neoplastic Cells, Circulating* / pathology
  • Prognosis
  • Stomach Neoplasms* / diagnosis

Substances

  • Biomarkers, Tumor